Articles tagged "Alloantibodies"

2019 American Transplant Congress
ABMR In Low-single Dose Thymoglobulin Induction Protocol In Renal Transplant Recepients From A Tertiary Care Centre In A Developing Country
R. Parthasarathy¹, M. Mohammed¹, P. Koshy², I. Pradeep², M. Mathew¹, G. Abraham¹
¹Nephrology, Madras Medical Mission, Chennai, India, ²Pathology, Madras Medical Mission, Chennai, India
*Purpose: Fool proof induction therapy in low sensitized patients is still elusive. There is a thin line between over immunosuppression and infection . Conventional rabbit…
2019 American Transplant Congress
Clazakizumab as an Agent to Reduce Donor Specific HLA Antibodies and Improve Outcomes in Patients with Chronic & Active Antibody-Mediated Rejection Post-Kidney Transplantation
S. C. Jordan¹, N. Ammerman¹, M. Toyoda², E. Huang¹, C. C. Nast³, A. Peng¹, S. Sethi¹, R. Najjar¹, I. Kim¹, K. Lim¹, J. Choi¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Department of Pathology, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production.…
2019 American Transplant Congress
Human Leukocyte Antigen Class I (HLA-I) Antibodies in Patients Undergoing Liver Transplantation: Implications for Platelet Transfusion Support
M. Wong¹, R. Narra², M. Selim¹, M. A. Zimmerman¹, A. Padmanabhan³, J. C. Hong¹
¹Div. of Transplant Surgery, Medical College of Wisconsin, Milwaukee, WI, ²Div. of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI, ³Medical College of Wisconsin and BloodCenter of Wisconsin, Milwaukee, WI
*Purpose: Liver transplantation is a high platelet transfusion (PLT) setting due to the elevated incidence of thrombocytopenia and bleeding. HLA-I antibodies are thought to have…
2019 American Transplant Congress
Daratumumab for Treatment of Antibody-Mediated Rejection in a Kidney Transplant Recipient
S. C. Jordan¹, R. Vescio², M. Toyoda³, N. Ammerman¹, E. Huang¹, A. Peng¹, S. Sethi¹, R. Najjar¹, K. Lim¹, A. Vo¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Ctr, Los Angeles, CA, ²Cedars-Sinai Medical Ctr, Los Angeles, CA, ³Transplant Immunology Lab, Cedars-Sinai Medical Ctr, Los Angeles, CA
*Purpose: Antibody-Mediated Rejection (ABMR) is a severe form of rejection mediated by B-cells, plasma cells and antibodies. The consequences to the patients with ABMR are…
2019 American Transplant Congress
Not All Donor-Specific Antibodies Are Equal: Predictors of Risk of Chronic Lung Allograft Dysfunction
C. J. Iasella¹, C. R. Ensor², M. Marrari³, M. Mangiola³, C. A. Moore¹, M. R. Morrell⁴, J. Pilewski⁴, J. F. McDyer⁴, A. Zeevi³
¹Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Florida Hospital Transplant Institute, AdventHealth Orlando, Orlando, FL, ³Pathology, University of Pittsburgh, Pittsburgh, PA, ⁴Medicine, University of Pittsburgh, Pittsburgh, PA
*Purpose: Donor-specific HLA antibodies (DSA) have been previously associated with chronic lung allograft dysfunction (CLAD). However, the DSA characteristics that predict risk of CLAD are…
2019 American Transplant Congress
Use Of Perirenal Adipose Tissue As A Source Of Donor Cells Allowing Evaluation Of Endothelial Inflammation And Quality Of Expanded Criteria Kidneys
R. Boissier¹, L. Lyonnet², P. Francois³, M. Meunier⁴, B. Gondran-Tellier⁵, T. Legris⁶, J. Magalon⁵, C. Picard⁷, F. Dignat George⁵, E. Lechevallier⁸, G. Karsenty⁸, F. Sabatier⁹, P. Paul¹
¹INSERM 1263, Centre de recherche en cardiovasculaire et nutrition, INSERM, Aix Marseille Univ, Assistance Publique Hopitaux Marseille, Marseille, France, ²Vascular Biology and Hematology department, Assistance publique Hopitaux Marseille (AP-HM), Marseille, France, ³INSERM 1263, Centre de recherche en cardiovasculaire et nutrition, INSERM, Aix Marseille Univ., Marseille, France, ⁴Nephrology Dialysis and Renal Transplantation Center, AP-HM, Marseille, France, ⁵INSERM 1263, C2VN, INSERM, Aix Marseille Univ., Marseille, France, ⁶Nephrology Dialysis and Renal Transplantation Center, AP-HM, Marseille, France, ⁷Etablissement Français du Sang, Alpes Méditerranée, Marseille, France, ⁸Urology and Transplantation Unit , AP-HM, Marseille, France, ⁹INSERM 1263, Centre de recherche en cardiovasculaire et nutrition, INSERM, Aix Marseille Univ, Marseille, France
*Purpose: Use of expanded-criteria donor (ECD) kidneys is a perspective to overcome organ shortage. Age and donor-related co-morbidy factors are known to affect graft function…
2019 American Transplant Congress
Cluster Analysis of Microvascular Inflammation in Indication Biopsies Unveils Distinct Pathological and Immunological Phenotypes with Prognostic Implications
J. Malheiro¹, A. Silva¹, S. Santos¹, S. Tafulo², L. Martins¹, L. Dias¹, A. Castro-Henriques¹
¹Centro Hospitalar do Porto, Porto, Portugal, ²IPST_Porto, Porto, Portugal
*Purpose: We aimed to define distinct pathological and immunological clusters of 80 cases of MVI diagnosed in indication biopsies and evaluate their prognostic implications.*Methods: The…
2019 American Transplant Congress
Platelets Augment Granzyme K Production By Macrophages In Antibody-mediated Rejection
J. Dhar, K. Keslar, R. Fan, N. Dvorina, W. Baldwin
Cleveland Clinic Main Campus, Lerner Research Institute, Cleveland, OH
*Purpose: When antibodies bind to MHC antigens on endothelial cells a cascade of responses is initiated including exocytosis of adhesion molecules followed by attachment and…
2019 American Transplant Congress
Donor-Derived Cell-Free DNA is Associated Specifically with Antibody Mediated Injury in Patients with Renal Allograft Dysfunction
B. Obrisca¹, C. Blosser², I. De Castro², C. Johnson², B. Sorohan¹, L. Sibulesky², R. Bakthavatsalam², G. Ismail¹, N. Leca²
¹Fundeni Clinical Institute, Bucharest, Romania, ²University of Washington, Seattle, WA
*Purpose: Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a noninvasive biomarker to differentiate rejection from other types of injury in renal allografts.*Methods: We analyzed…
2019 American Transplant Congress
Immediate Post Reperfusion In Vivo Transcriptional Responses of Individual Human Renal Allograft Cell Populations to Circulating Anti-Angiotensin II Type I Receptor Antibody
C. M. Castro -Rojas¹, N. Salomonis², K. Chetal², R. R. Alloway³, E. Woodle³, D. A. Hildeman¹
¹Immunobiology, Cincinnati Children's Hospital, Cincinnati, OH, ²Biomedical Informatics, Cincinnati Children's Hospital, Cincinnati, OH, ³Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH
*Purpose: Pre-existing anti-angiotensin II type I receptor (AT1R) antibodies can be a significant driver of allograft rejection. Indeed, prior work has shown that AT1R antibodies…